Head-to-head · Value Score
Alan Meds vs FuturHealth
Two GLP-1 deals, scored on the same six factors. Alan Meds lands a Value Score of 90, FuturHealth a 58. Here's who gives you the honest lower price — and where each one bites back.
Alan Meds
#7 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameFuturHealth
#366 · Grade C · Watch List
Est. first month
From $199/mo (compounded)
Save ~85% vs brand-nameThe verdict
Alan Meds takes it on Value Score, 90 to 58 — an est. $99/mo first month, with no teaser step-up baked in. FuturHealth isn't out of it: Shoppers who want brand-name and compounded GLP-1s with registered-dietitian coaching.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Alan Meds | FuturHealth |
|---|---|---|
| Value Score | 90 (A) | 58 (C) |
| Est. first month | $99/mo | From $199/mo (compounded) |
| Save vs brand-name | ~93% | ~85% |
| Semaglutide | $99/mo | From $199/mo (compounded) |
| Tirzepatide | $145/mo | Not disclosed |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Alan Meds
Double-digit semaglutide ($99) and a $145 tirzepatide, both nationwide, with an oral route for the needle-shy.
Why it's a deal
- $99 flat semaglutide and a low $145 tirzepatide
- Available in all 50 states
- Offers an oral/sublingual route
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Newer operator with a thin public track record
FuturHealth
FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added
Why it's a deal
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
The fine print
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Alan Meds is ranked on the Alan Meds alternatives board, and the same list for the other side is on alternatives to FuturHealth.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.